PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironmentWing Lam(Yale University), Yung-Chi Cheng(Yale University)Scientific ReportsMarch 30, 201510.1038/srep09384Cited by 111SaveCiteExport RISWatch citationsRelated PapersYIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity|Frontiers in Pharmacology|2023|8